Cargando…

Patient reported symptoms associated with quality of life during chemo‐ or immunotherapy for bladder cancer patients with advanced disease

BACKGROUND: Bladder cancer (BC) patients with advanced disease have poor outcomes. The use of patient‐reported outcomes (PROs) could lead to improvements in symptom management and hence quality of life (QoL). The aim of this study is to report correlations between selected PROs and QoL and thus to p...

Descripción completa

Detalles Bibliográficos
Autores principales: Taarnhøj, Gry A., Johansen, Christoffer, Lindberg, Henriette, Basch, Ethan, Dueck, Amylou, Pappot, Helle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196058/
https://www.ncbi.nlm.nih.gov/pubmed/32154663
http://dx.doi.org/10.1002/cam4.2958
_version_ 1783528647700774912
author Taarnhøj, Gry A.
Johansen, Christoffer
Lindberg, Henriette
Basch, Ethan
Dueck, Amylou
Pappot, Helle
author_facet Taarnhøj, Gry A.
Johansen, Christoffer
Lindberg, Henriette
Basch, Ethan
Dueck, Amylou
Pappot, Helle
author_sort Taarnhøj, Gry A.
collection PubMed
description BACKGROUND: Bladder cancer (BC) patients with advanced disease have poor outcomes. The use of patient‐reported outcomes (PROs) could lead to improvements in symptom management and hence quality of life (QoL). The aim of this study is to report correlations between selected PROs and QoL and thus to present symptoms that influence QoL. Identification of these symptoms during treatment can lead to earlier symptom management and thus secure improvements in QoL. METHODS: BC patients in chemo‐ or immunotherapy for locally advanced or metastatic disease reported weekly PROs for the duration of their treatment. The PROs included EORTC QLQ‐C30 and QLQ‐BLM30 and 45 selected PRO‐CTCAE items. Spearman's correlation analysis was performed for all PRO‐CTCAE items and QLQ‐C30 global QoL and subdomains. RESULTS: In this study, 78 BC patients reported 724 questionnaires. Spearman's analysis showed significant correlations between almost all PRO‐CTCAE items and the expected domain of QoL. The PRO‐CTCAE items with the strongest correlations with QoL were anxiety (F, frequency item) and emotional function (r (s) = −0.603, P < .0001), concentration (S, severity item) and cognitive function (r (s) = −0.704, P < .0001), discouraged (F) and emotional function (r (s) = −0.659, P < .0001), fatigue (S) and role function (r (s) = −0.659, P < .0001) and sad (F) and emotional function (r (s) = −0.711, P < .0001). The weakest correlations were found for the PRO‐CTCAE items urinary frequency, incontinence and urge, all with variations in the direction and significance of the correlations. CONCLUSIONS: This study delivers information on which PROs may influence QoL for patients in clinical trials or daily clinic. Psychological issues have a strong impact on QoL and should be dealt with during treatment to secure the best possible QoL for BC patients.
format Online
Article
Text
id pubmed-7196058
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-71960582020-05-04 Patient reported symptoms associated with quality of life during chemo‐ or immunotherapy for bladder cancer patients with advanced disease Taarnhøj, Gry A. Johansen, Christoffer Lindberg, Henriette Basch, Ethan Dueck, Amylou Pappot, Helle Cancer Med Clinical Cancer Research BACKGROUND: Bladder cancer (BC) patients with advanced disease have poor outcomes. The use of patient‐reported outcomes (PROs) could lead to improvements in symptom management and hence quality of life (QoL). The aim of this study is to report correlations between selected PROs and QoL and thus to present symptoms that influence QoL. Identification of these symptoms during treatment can lead to earlier symptom management and thus secure improvements in QoL. METHODS: BC patients in chemo‐ or immunotherapy for locally advanced or metastatic disease reported weekly PROs for the duration of their treatment. The PROs included EORTC QLQ‐C30 and QLQ‐BLM30 and 45 selected PRO‐CTCAE items. Spearman's correlation analysis was performed for all PRO‐CTCAE items and QLQ‐C30 global QoL and subdomains. RESULTS: In this study, 78 BC patients reported 724 questionnaires. Spearman's analysis showed significant correlations between almost all PRO‐CTCAE items and the expected domain of QoL. The PRO‐CTCAE items with the strongest correlations with QoL were anxiety (F, frequency item) and emotional function (r (s) = −0.603, P < .0001), concentration (S, severity item) and cognitive function (r (s) = −0.704, P < .0001), discouraged (F) and emotional function (r (s) = −0.659, P < .0001), fatigue (S) and role function (r (s) = −0.659, P < .0001) and sad (F) and emotional function (r (s) = −0.711, P < .0001). The weakest correlations were found for the PRO‐CTCAE items urinary frequency, incontinence and urge, all with variations in the direction and significance of the correlations. CONCLUSIONS: This study delivers information on which PROs may influence QoL for patients in clinical trials or daily clinic. Psychological issues have a strong impact on QoL and should be dealt with during treatment to secure the best possible QoL for BC patients. John Wiley and Sons Inc. 2020-03-10 /pmc/articles/PMC7196058/ /pubmed/32154663 http://dx.doi.org/10.1002/cam4.2958 Text en © 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Cancer Research
Taarnhøj, Gry A.
Johansen, Christoffer
Lindberg, Henriette
Basch, Ethan
Dueck, Amylou
Pappot, Helle
Patient reported symptoms associated with quality of life during chemo‐ or immunotherapy for bladder cancer patients with advanced disease
title Patient reported symptoms associated with quality of life during chemo‐ or immunotherapy for bladder cancer patients with advanced disease
title_full Patient reported symptoms associated with quality of life during chemo‐ or immunotherapy for bladder cancer patients with advanced disease
title_fullStr Patient reported symptoms associated with quality of life during chemo‐ or immunotherapy for bladder cancer patients with advanced disease
title_full_unstemmed Patient reported symptoms associated with quality of life during chemo‐ or immunotherapy for bladder cancer patients with advanced disease
title_short Patient reported symptoms associated with quality of life during chemo‐ or immunotherapy for bladder cancer patients with advanced disease
title_sort patient reported symptoms associated with quality of life during chemo‐ or immunotherapy for bladder cancer patients with advanced disease
topic Clinical Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196058/
https://www.ncbi.nlm.nih.gov/pubmed/32154663
http://dx.doi.org/10.1002/cam4.2958
work_keys_str_mv AT taarnhøjgrya patientreportedsymptomsassociatedwithqualityoflifeduringchemoorimmunotherapyforbladdercancerpatientswithadvanceddisease
AT johansenchristoffer patientreportedsymptomsassociatedwithqualityoflifeduringchemoorimmunotherapyforbladdercancerpatientswithadvanceddisease
AT lindberghenriette patientreportedsymptomsassociatedwithqualityoflifeduringchemoorimmunotherapyforbladdercancerpatientswithadvanceddisease
AT baschethan patientreportedsymptomsassociatedwithqualityoflifeduringchemoorimmunotherapyforbladdercancerpatientswithadvanceddisease
AT dueckamylou patientreportedsymptomsassociatedwithqualityoflifeduringchemoorimmunotherapyforbladdercancerpatientswithadvanceddisease
AT pappothelle patientreportedsymptomsassociatedwithqualityoflifeduringchemoorimmunotherapyforbladdercancerpatientswithadvanceddisease